MICAFUNGIN VS CASPOFUNGIN FOR THE TREATMENT OF SYSTEMIC CANDIDA INFECTIONS: A COST-EFFECTIVENESS ANALYSIS FOR GERMANY

被引：0
|
作者：
Felder, S. [1 ]
Grabe, K. [2 ]
Mayrhofer, T. [1 ]
Decker, S. [1 ]
机构：
[1] Duisburg Essen Univ, Essen, Germany
[2] Astellas Pharma GmbH, Munich, Germany
来源：
VALUE IN HEALTH | 2009年 / 12卷 / 07期
关键词：
D O I：
10.1016/S1098-3015(10)75108-1
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A426 / A427
页数：2
相关论文
共 50 条
  • [1] MICAFUNGIN VERSUS CASPOFUNGIN FOR THE TREATMENT OF SYSTEMIC CANDIDA INFECTIONS: A COST-EFFECTIVENESS ANALYSIS FOR SWITZERLAND
    Felder, S.
    Mayrhofer, T.
    [J]. VALUE IN HEALTH, 2014, 17 (03) : A275 - A275
  • [2] Cost-effectiveness analysis of micafungin versus caspofungin for treatment of systemic Candida infections in the UK
    Sidhu, M. K.
    van Engen, A. K.
    Kleintjens, J.
    Schoeman, O.
    Palazzo, M.
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2009, 25 (08) : 2049 - 2059
  • [3] A COST-EFFECTIVENESS ANALYSIS OF MICAFUNGIN VERSUS CASPOFUNGIN FOR TREATMENT OF SYSTEMIC CANDIDA INFECTIONS IN ITALY
    Sidhu, M. K.
    Van Engen, A. K.
    Switjnk, A. B.
    Concia, E.
    [J]. VALUE IN HEALTH, 2009, 12 (07) : A425 - A425
  • [4] COST-EFFECTIVENESS ANALYSIS OF MICAFUNGIN VERSUS CASPOFUNGIN IN THE TREATMENT OF INVASIVE CANDIDA INFECTION IN CHINA
    Wang, C.
    Dong, H.
    Sun, L.
    [J]. VALUE IN HEALTH, 2014, 17 (03) : A275 - A276
  • [5] COST-EFFECTIVENESS ANALYSIS OF MICAFUNGIN VERSUS LIPOSOMAL AMPHOTERICIN B IN THE TREATMENT OF PAEDIATRIC PATIENTS WITH SYSTEMIC CANDIDA INFECTIONS
    Odeyemi, A.
    Hart, W. M.
    Odeyemi, I. I.
    Musingarimi, P.
    [J]. VALUE IN HEALTH, 2010, 13 (03) : A189 - A189
  • [6] A cost-effectiveness analysis of caspofungin vs. liposomal amphotericin B for treatment of suspected fungal infections in the UK
    Bruynesteyn, Karin
    Gant, Vanya
    McKenzie, Catherine
    Pagliuca, Tony
    Poynton, Chris
    Kumar, Ritesh N.
    Jansen, Jeroen P.
    [J]. EUROPEAN JOURNAL OF HAEMATOLOGY, 2007, 78 (06) : 532 - 539
  • [7] DOXYCYCLINE VS AZITHROMYCIN IN THE TREATMENT OF WOMEN WITH CHLAMYDIA INFECTIONS - A COST-EFFECTIVENESS ANALYSIS
    MAGID, D
    DOUGLAS, J
    SCHWARTZ, J
    [J]. CLINICAL RESEARCH, 1993, 41 (01): : A62 - A62
  • [8] Cost-effectiveness of caspofungin versus liposomal amphotericin B in the treatment of systemic fungal infections: a systematic review of economic analyses
    Mistro, Sostenes
    Rosa, Lorena
    Gomes, Barbara
    Miranda, Ligia
    Badaro, Roberto
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2016, 16 (04) : 465 - 473
  • [9] COST EFFECTIVENESS OF DE-ESCALATION FROM MICAFUNGIN IN THE TREATMENT OF PATIENTS WITH SYSTEMIC CANDIDA INFECTIONS COMPARED TO TRADITIONAL ESCALATION FROM FLUCONAZOLE
    Masterton, R.
    Casamayor, M.
    Musingarimi, P.
    Van Engen, A.
    Odufowora-Sita, O.
    [J]. VALUE IN HEALTH, 2011, 14 (07) : A279 - A279
  • [10] Treatment of depression in Germany An analysis of cost-effectiveness with remission
    Voelkl, M.
    Fritze, J.
    Hoeffler, J.
    Roth, G.
    Ruether, E.
    Schreiber, W.
    Schwarzer, W.
    [J]. GESUNDHEITSOEKONOMIE UND QUALITAETSMANAGEMENT, 2007, 12 (01): : 35 - 43
12345